Picture2.jpg
ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 02, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative...
Picture2.jpg
ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy™ Image Capture Software in Atopic Dermatitis Clinical Trials
August 25, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and CAMBRIDGE, Mass. and SINGAPORE, Aug. 25, 2022 (GLOBE NEWSWIRE) -- BelleTorus Corporation (“Belle.ai”) and ASLAN Pharmaceuticals (Nasdaq: ASLN), today announced that ASLAN has...
Picture2.jpg
ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022
August 22, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion Leader (KOL) participationPipeline and business update, translational and clinical data...
Picture2.jpg
ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 12, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
- Company maintains healthy operating position with US$78.1 million in cash, cash equivalents and short-term investments as of June 30, 2022, runway through late 2023- Three abstracts showcasing new...
Picture2.jpg
ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress
August 11, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
Picture2.jpg
ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis
June 07, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, June 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
Picture2.jpg
ASLAN Pharmaceuticals to Host Third Webinar in A⁴ KOL Series: ‘Dialogues With International Thought Leaders in Dermatology’
June 06, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, June 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
Picture2.jpg
ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 31, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, May 31, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
Picture2.jpg
ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting
May 20, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
Picture2.jpg
ASLAN Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, May 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...